glp 1 and chronic kidney disease GLP-1 Receptor Agonists Protection Glucagon-like peptide 1(GLP-1) receptor agonists

It can speed up muscle growth, fat loss, and recovery, but it bypasses the bodys natural endocrine regulation, which may increase the risk of side effects like insulin resistance, fluid retention, and joint pain

Diabetes 67(9):17101719 Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, VADT Investigators et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes

Endocrinology 149:40594068 [DOI] [PMC free article] [PubMed] [Google Scholar] Knauf C, Cani PD, Ait-Belgnaoui A, Benani A, Dray C, Cabou C, Colom A, Uldry M, Rastrelli S, Sabatier E, Godet N, Waget A, Pnicaud L, Valet P, Burcelin R 2008 Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure

This could involve medical expert testimony or scientific studies supporting the connection between the drug and the reported side effects